| 3.8018 0.802 (26.73%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.62  |
1-year : | 6.57 |
| Resists | First : | 4.82 |
Second : | 5.62 |
| Pivot price | 2.05 |
|||
| Supports | First : | 2.85 |
Second : | 1.63 |
| MAs | MA(5) : | 2.62 |
MA(20) : | 1.99 |
| MA(100) : | 1.99 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 84.3 |
D(3) : | 88.1 |
| RSI | RSI(14): 86.8 |
|||
| 52-week | High : | 4.82 | Low : | 1.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CLYM ] has closed It is unclear right now based on current values. 316.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.82 - 4.84 | 4.84 - 4.85 |
| Low: | 3.05 - 3.06 | 3.06 - 3.08 |
| Close: | 3.78 - 3.8 | 3.8 - 3.82 |
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Mon, 15 Dec 2025
Ra Capital Management, L.P. Buys 213,099 Shares of Climb Bio (NASDAQ:CLYM) Stock - MarketBeat
Mon, 15 Dec 2025
Insider Buying: Climb Bio (NASDAQ:CLYM) Director Buys 101,462 Shares of Stock - MarketBeat
Mon, 15 Dec 2025
Climb bio sees $754k in purchases from RA Capital funds - Investing.com
Mon, 15 Dec 2025
Data-Rich Year Ahead - Will 2026 Readouts Lift Climb Bio Higher - RTTNews
Tue, 25 Nov 2025
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Mon, 10 Nov 2025
Climb Bio, Inc. Reports Q3 2025 Financial Results - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 73.4 (%) |
| Shares Short | 1,880 (K) |
| Shares Short P.Month | 1,290 (K) |
| EPS | -0.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.4 % |
| Return on Equity (ttm) | -25.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -6.45 |
| PEG Ratio | 0 |
| Price to Book value | 1.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|